Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
53
SPHRY Quote, Financials, Valuation and Earnings
Last price:
$3.15
Seasonality move
:
8.68%
Day range:
$3.15 - $3.15
52-week range:
$0.47 - $3.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.62x
P/B ratio:
1.90x
Volume:
1K
Avg. volume:
1.6K
1-year change:
319.41%
Market cap:
$131.7M
Revenue:
$3.2M
EPS (TTM):
-$0.05
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SPHRY
Starpharma Holdings Ltd.
|
-- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $11.00 |
|
CSLLY
CSL Ltd.
|
-- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $18.94 |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SPHRY
Starpharma Holdings Ltd.
|
$3.15 | -- | $131.7M | -- | $0.00 | 0% | 14.62x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.44 | $11.00 | $62.4M | -- | $0.00 | 0% | 3.58x |
|
CSLLY
CSL Ltd.
|
$52.11 | -- | $50.6B | 36.28x | $0.81 | 2.8% | 3.31x |
|
IMMP
Immutep Ltd.
|
$2.80 | $9.50 | $407.6M | -- | $0.00 | 0% | 153.33x |
|
KZIA
Kazia Therapeutics Ltd.
|
$8.45 | $18.94 | $95.8M | -- | $0.00 | 0% | 381.81x |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
$0.0079 | -- | $13.3M | -- | $0.00 | 0% | 0.14x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SPHRY
Starpharma Holdings Ltd.
|
9.65% | 3.556 | -- | 4.93x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | 2.224 | -- | -- |
|
CSLLY
CSL Ltd.
|
39.2% | -0.064 | -- | 0.84x |
|
IMMP
Immutep Ltd.
|
-- | 0.527 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 4.448 | 5.57% | 0.07x |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
-- | -3.348 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SPHRY
Starpharma Holdings Ltd.
|
-- | -- | -40.48% | -43.48% | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CSLLY
CSL Ltd.
|
$4.3B | $2B | 8.85% | 14.06% | 33.52% | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
-- | -- | -- | -- | -- | -- |
Starpharma Holdings Ltd. vs. Competitors
-
Which has Higher Returns SPHRY or ATHE?
Alterity Therapeutics Ltd. has a net margin of -- compared to Starpharma Holdings Ltd.'s net margin of --. Starpharma Holdings Ltd.'s return on equity of -43.48% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SPHRYStarpharma Holdings Ltd.-- -- $15.9M ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About SPHRY or ATHE?
Starpharma Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $11.00 which suggests that it could grow by 219.68%. Given that Alterity Therapeutics Ltd. has higher upside potential than Starpharma Holdings Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than Starpharma Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SPHRYStarpharma Holdings Ltd.0 0 0 ATHEAlterity Therapeutics Ltd.1 0 0 -
Is SPHRY or ATHE More Risky?
Starpharma Holdings Ltd. has a beta of 0.866, which suggesting that the stock is 13.401% less volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.114, suggesting its less volatile than the S&P 500 by 88.643%.
-
Which is a Better Dividend Stock SPHRY or ATHE?
Starpharma Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Starpharma Holdings Ltd. pays -- of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPHRY or ATHE?
Starpharma Holdings Ltd. quarterly revenues are --, which are smaller than Alterity Therapeutics Ltd. quarterly revenues of --. Starpharma Holdings Ltd.'s net income of -- is lower than Alterity Therapeutics Ltd.'s net income of --. Notably, Starpharma Holdings Ltd.'s price-to-earnings ratio is -- while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Starpharma Holdings Ltd. is 14.62x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPHRYStarpharma Holdings Ltd.14.62x -- -- -- ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns SPHRY or CSLLY?
CSL Ltd. has a net margin of -- compared to Starpharma Holdings Ltd.'s net margin of 24.44%. Starpharma Holdings Ltd.'s return on equity of -43.48% beat CSL Ltd.'s return on equity of 14.06%.
Company Gross Margin Earnings Per Share Invested Capital SPHRYStarpharma Holdings Ltd.-- -- $15.9M CSLLYCSL Ltd.52.1% $2.07 $32.5B -
What do Analysts Say About SPHRY or CSLLY?
Starpharma Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand CSL Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Starpharma Holdings Ltd. has higher upside potential than CSL Ltd., analysts believe Starpharma Holdings Ltd. is more attractive than CSL Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SPHRYStarpharma Holdings Ltd.0 0 0 CSLLYCSL Ltd.0 0 0 -
Is SPHRY or CSLLY More Risky?
Starpharma Holdings Ltd. has a beta of 0.866, which suggesting that the stock is 13.401% less volatile than S&P 500. In comparison CSL Ltd. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.939%.
-
Which is a Better Dividend Stock SPHRY or CSLLY?
Starpharma Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CSL Ltd. offers a yield of 2.8% to investors and pays a quarterly dividend of $0.81 per share. Starpharma Holdings Ltd. pays -- of its earnings as a dividend. CSL Ltd. pays out 43.93% of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SPHRY or CSLLY?
Starpharma Holdings Ltd. quarterly revenues are --, which are smaller than CSL Ltd. quarterly revenues of $8.2B. Starpharma Holdings Ltd.'s net income of -- is lower than CSL Ltd.'s net income of $2B. Notably, Starpharma Holdings Ltd.'s price-to-earnings ratio is -- while CSL Ltd.'s PE ratio is 36.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Starpharma Holdings Ltd. is 14.62x versus 3.31x for CSL Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPHRYStarpharma Holdings Ltd.14.62x -- -- -- CSLLYCSL Ltd.3.31x 36.28x $8.2B $2B
-
Which has Higher Returns SPHRY or IMMP?
Immutep Ltd. has a net margin of -- compared to Starpharma Holdings Ltd.'s net margin of --. Starpharma Holdings Ltd.'s return on equity of -43.48% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SPHRYStarpharma Holdings Ltd.-- -- $15.9M IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About SPHRY or IMMP?
Starpharma Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 239.29%. Given that Immutep Ltd. has higher upside potential than Starpharma Holdings Ltd., analysts believe Immutep Ltd. is more attractive than Starpharma Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SPHRYStarpharma Holdings Ltd.0 0 0 IMMPImmutep Ltd.1 0 0 -
Is SPHRY or IMMP More Risky?
Starpharma Holdings Ltd. has a beta of 0.866, which suggesting that the stock is 13.401% less volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.756, suggesting its more volatile than the S&P 500 by 75.579%.
-
Which is a Better Dividend Stock SPHRY or IMMP?
Starpharma Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Starpharma Holdings Ltd. pays -- of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPHRY or IMMP?
Starpharma Holdings Ltd. quarterly revenues are --, which are smaller than Immutep Ltd. quarterly revenues of --. Starpharma Holdings Ltd.'s net income of -- is lower than Immutep Ltd.'s net income of --. Notably, Starpharma Holdings Ltd.'s price-to-earnings ratio is -- while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Starpharma Holdings Ltd. is 14.62x versus 153.33x for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPHRYStarpharma Holdings Ltd.14.62x -- -- -- IMMPImmutep Ltd.153.33x -- -- --
-
Which has Higher Returns SPHRY or KZIA?
Kazia Therapeutics Ltd. has a net margin of -- compared to Starpharma Holdings Ltd.'s net margin of --. Starpharma Holdings Ltd.'s return on equity of -43.48% beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital SPHRYStarpharma Holdings Ltd.-- -- $15.9M KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About SPHRY or KZIA?
Starpharma Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $18.94 which suggests that it could grow by 124.09%. Given that Kazia Therapeutics Ltd. has higher upside potential than Starpharma Holdings Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than Starpharma Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SPHRYStarpharma Holdings Ltd.0 0 0 KZIAKazia Therapeutics Ltd.1 0 0 -
Is SPHRY or KZIA More Risky?
Starpharma Holdings Ltd. has a beta of 0.866, which suggesting that the stock is 13.401% less volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.775, suggesting its more volatile than the S&P 500 by 77.474%.
-
Which is a Better Dividend Stock SPHRY or KZIA?
Starpharma Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Starpharma Holdings Ltd. pays -- of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPHRY or KZIA?
Starpharma Holdings Ltd. quarterly revenues are --, which are smaller than Kazia Therapeutics Ltd. quarterly revenues of --. Starpharma Holdings Ltd.'s net income of -- is lower than Kazia Therapeutics Ltd.'s net income of --. Notably, Starpharma Holdings Ltd.'s price-to-earnings ratio is -- while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Starpharma Holdings Ltd. is 14.62x versus 381.81x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPHRYStarpharma Holdings Ltd.14.62x -- -- -- KZIAKazia Therapeutics Ltd.381.81x -- -- --
-
Which has Higher Returns SPHRY or LVCLF?
Algorae Pharmaceuticals Ltd. has a net margin of -- compared to Starpharma Holdings Ltd.'s net margin of --. Starpharma Holdings Ltd.'s return on equity of -43.48% beat Algorae Pharmaceuticals Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SPHRYStarpharma Holdings Ltd.-- -- $15.9M LVCLFAlgorae Pharmaceuticals Ltd.-- -- -- -
What do Analysts Say About SPHRY or LVCLF?
Starpharma Holdings Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Algorae Pharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Starpharma Holdings Ltd. has higher upside potential than Algorae Pharmaceuticals Ltd., analysts believe Starpharma Holdings Ltd. is more attractive than Algorae Pharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SPHRYStarpharma Holdings Ltd.0 0 0 LVCLFAlgorae Pharmaceuticals Ltd.0 0 0 -
Is SPHRY or LVCLF More Risky?
Starpharma Holdings Ltd. has a beta of 0.866, which suggesting that the stock is 13.401% less volatile than S&P 500. In comparison Algorae Pharmaceuticals Ltd. has a beta of -0.656, suggesting its less volatile than the S&P 500 by 165.606%.
-
Which is a Better Dividend Stock SPHRY or LVCLF?
Starpharma Holdings Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Algorae Pharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Starpharma Holdings Ltd. pays -- of its earnings as a dividend. Algorae Pharmaceuticals Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SPHRY or LVCLF?
Starpharma Holdings Ltd. quarterly revenues are --, which are smaller than Algorae Pharmaceuticals Ltd. quarterly revenues of --. Starpharma Holdings Ltd.'s net income of -- is lower than Algorae Pharmaceuticals Ltd.'s net income of --. Notably, Starpharma Holdings Ltd.'s price-to-earnings ratio is -- while Algorae Pharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Starpharma Holdings Ltd. is 14.62x versus 0.14x for Algorae Pharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SPHRYStarpharma Holdings Ltd.14.62x -- -- -- LVCLFAlgorae Pharmaceuticals Ltd.0.14x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Buy
72
SEZL alert for Feb 28
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
